185 related articles for article (PubMed ID: 37877513)
1. Incidence and Bayesian Mapping of Myeloid Hematologic Malignancies in Sardinia, Italy.
Broccia G; Carter J; Ozsin-Ozler C; De Matteis S; Cocco P
Cancer Control; 2023; 30():10732748231202906. PubMed ID: 37877513
[TBL] [Abstract][Full Text] [Related]
2. Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Cote d'Or (Burgundy, France).
Maynadié M; Girodon F; Manivet-Janoray I; Mounier M; Mugneret F; Bailly F; Favre B; Caillot D; Petrella T; Flesch M; Carli PM
Haematologica; 2011 Jan; 96(1):55-61. PubMed ID: 20971817
[TBL] [Abstract][Full Text] [Related]
3. Community-acquired infections and their association with myeloid malignancies.
Titmarsh GJ; McMullin MF; McShane CM; Clarke M; Engels EA; Anderson LA
Cancer Epidemiol; 2014 Feb; 38(1):56-61. PubMed ID: 24275260
[TBL] [Abstract][Full Text] [Related]
4. Familial aggregation of acute myeloid leukemia and myelodysplastic syndromes.
Goldin LR; Kristinsson SY; Liang XS; Derolf AR; Landgren O; Björkholm M
J Clin Oncol; 2012 Jan; 30(2):179-83. PubMed ID: 22162584
[TBL] [Abstract][Full Text] [Related]
5. Incidence, survival and prevalence of myeloid malignancies in Europe.
Visser O; Trama A; Maynadié M; Stiller C; Marcos-Gragera R; De Angelis R; Mallone S; Tereanu C; Allemani C; Ricardi U; Schouten HC;
Eur J Cancer; 2012 Nov; 48(17):3257-66. PubMed ID: 22770878
[TBL] [Abstract][Full Text] [Related]
6. Recent improvement in completeness of incidence data on acute myeloid leukemia in US cancer registries.
Polednak AP
J Registry Manag; 2014; 41(2):77-84. PubMed ID: 25153013
[TBL] [Abstract][Full Text] [Related]
7. Hematologic malignancies following immune checkpoint inhibition for solid tumors.
van Eijs MJM; van der Wagen LE; Mous R; Leguit RJ; van de Corput L; van Lindert ASR; Suelmann BBM; Kamphuis AM; Nierkens S; Suijkerbuijk KPM
Cancer Immunol Immunother; 2023 Jan; 72(1):249-255. PubMed ID: 35691988
[TBL] [Abstract][Full Text] [Related]
8. Is survival in myeloid malignancies really improving? A retrospective 15-year population-based study.
Osca-Gelis G; Puig-Vives M; Saez M; Gallardo D; Lloveras N; Guàrdia R; Marcos-Gragera R
Leuk Lymphoma; 2015 Apr; 56(4):896-902. PubMed ID: 25058372
[TBL] [Abstract][Full Text] [Related]
9. Ethnic and border differences on blood cancer presentation and outcomes: A Texas population-based study.
Bencomo-Alvarez AE; Gonzalez MA; Rubio AJ; Olivas IM; Lara JJ; Padilla O; Orazi A; Corral J; Philipovskiy A; Gaur S; Mulla ZD; Dwivedi AK; Eiring AM
Cancer; 2021 Apr; 127(7):1068-1079. PubMed ID: 33616915
[TBL] [Abstract][Full Text] [Related]
10. [Haematological malignancies: incidence in Basse-Normandie, France, for 1997-2004].
Troussard X; Duchenet V; Cornet E; Mouchel D; Malet M; Collignon A
Rev Epidemiol Sante Publique; 2009 Jun; 57(3):151-8. PubMed ID: 19375876
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic epigenetics: an emerging clinical approach to hematologic malignancies.
Clin Adv Hematol Oncol; 2005 Mar; 3(3 Suppl 1):1-10; quiz 11-2. PubMed ID: 21438190
[No Abstract] [Full Text] [Related]
12. Epidemiology of Chronic Lymphocytic Leukemia in Sardinia, Italy (1974-2003).
Broccia G; Carter J; Ozsin-Ozler C; De Matteis S; Cocco P
Exp Hematol; 2023; 125-126():37-44. PubMed ID: 37567460
[TBL] [Abstract][Full Text] [Related]
13. Incidence of myeloid malignancies by subtype in Hong Kong and comparisons with Asian and white men and women in the United States.
Bassig BA; Hu W; Morton LM; Ji BT; Xu J; Linet MS; Kwong YL; Rothman N; Wong KF; Lan Q
Leuk Lymphoma; 2022 Aug; 63(8):1917-1924. PubMed ID: 35412943
[TBL] [Abstract][Full Text] [Related]
14. Underreporting of myeloid malignancies by United States cancer registries.
Craig BM; Rollison DE; List AF; Cogle CR
Cancer Epidemiol Biomarkers Prev; 2012 Mar; 21(3):474-81. PubMed ID: 22237987
[TBL] [Abstract][Full Text] [Related]
15. Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes.
Haferlach C; Rieder H; Lillington DM; Dastugue N; Hagemeijer A; Harbott J; Stilgenbauer S; Knuutila S; Johansson B; Fonatsch C
Genes Chromosomes Cancer; 2007 May; 46(5):494-9. PubMed ID: 17311250
[TBL] [Abstract][Full Text] [Related]
16. Myelodysplastic syndrome and benzene exposure among petroleum workers: an international pooled analysis.
Schnatter AR; Glass DC; Tang G; Irons RD; Rushton L
J Natl Cancer Inst; 2012 Nov; 104(22):1724-37. PubMed ID: 23111193
[TBL] [Abstract][Full Text] [Related]
17. MicroRNAs in myeloid malignancies.
Gordon JE; Wong JJ; Rasko JE
Br J Haematol; 2013 Jul; 162(2):162-76. PubMed ID: 23679825
[TBL] [Abstract][Full Text] [Related]
18. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H
Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088
[TBL] [Abstract][Full Text] [Related]
19. Incidence of myeloid neoplasms in Spain (2002-2013): a population-based study of the Spanish network of cancer registries.
Solans M; Sanvisens A; Ameijide A; Merino S; Rojas D; Alemán A; Banqueri E; Chico M; Marcos AI; de Castro V; Gil L; de Munain AL; Puigdemont M; Sánchez MJ; Perucha J; Ruiz-Armengol P; Chirlaque MD; Guevara M; Carulla M; Marcos-Gragera R
Sci Rep; 2022 Jan; 12(1):323. PubMed ID: 35013373
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study.
Granfeldt Østgård LS; Medeiros BC; Sengeløv H; Nørgaard M; Andersen MK; Dufva IH; Friis LS; Kjeldsen E; Marcher CW; Preiss B; Severinsen M; Nørgaard JM
J Clin Oncol; 2015 Nov; 33(31):3641-9. PubMed ID: 26304885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
